Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Flu Panel Approves Plan to Switch to H7N9 Strain for Pre-Pandemic Flu Vaccine
May 25, 2018
- Chuikyo Approves Insurance Reimbursement for 3 Medical Devices, with Listing Scheduled for June
May 25, 2018
- Chuikyo Tightens Physician Fee Rules for Self-Injections, Biosimilars Up for Individual Review
May 25, 2018
- Lynparza’s Breast Cancer Use, Chugai’s Obinutuzumab Clear MHLW Panel
May 24, 2018
- PMDA, FDA Team Up to Help Developing Countries to Facilitate Pediatric Drug Development
May 24, 2018
- Revisit Automatic Coverage for New Drugs, Discuss Mandatory CEA: MOF Panel Proposal
May 24, 2018
- No Specific Social Security Cost Target Discussed at CEFP, All Eyes on How to Handle FY2019-FY2021 Elderly Trough
May 22, 2018
- MHLW Presents Schedule for Discussions on Inclusion of 6 Vaccines in Public Vaccination Programs
May 21, 2018
- MHLW-MOF Negotiations Heating Up over Curtailment of Social Security Costs
May 18, 2018
- MHLW Finds 67 Suspected Violations in Sales Reps’ Advertising Activities; Cites Need for Official Reporting System
May 18, 2018
- Working Group Discussions Underway to Address Technical Issues for CEA before Confirmatory Analyses for 7 Products
May 18, 2018
- Warning against Use in Teenagers Should Be Removed from Tamiflu’s Package Insert: MHLW Panel
May 18, 2018
- Chuikyo Rep Frowns on Low Manufacturing Cost Disclosure, Says New Rule Might Need Revisiting
May 17, 2018
- Chuikyo Reps Chide Delay in Parmodia Listing
May 17, 2018
- Pricing OK’ed for Hemlibra, Parmodia; Prevymis 1st in 3 Years to Get At-Launch Premium for Innovation
May 17, 2018
- Japan Dodges “Priority Watch List,” but US Global IP Report Still Cites Concerns on Its Drug Pricing
May 16, 2018
- MHLW Approves Once-Daily Form of MSD’s HIV Drug Isentress
May 15, 2018
- Generic Industry to Ponder New Target Indicator for Post-80% Era
May 14, 2018
- Industry Asked for Legislation for Conditional Early Approval and Sakigake Designation Scheme: MHLW Panel
May 11, 2018
- Chugai’s Anticancer Agent Obinutuzumab Up for MHLW Panel Review on May 23
May 11, 2018
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…